Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers

References

• Baumgarten S, Gaba RC, Van Breemen RB. (2012). Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC–MS–MS. Biomed Chromatogr 26:1529–33.
   PubMed Web of Science ®Google Scholar
• Breedis C, Young G. (1954). The blood supply of neoplasms in the liver. Am J Pathol 30:969–77.
   PubMed Web of Science ®Google Scholar
• Chatziioannou AN, Siskos AP, Loxas D, et al. (2013). Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. J Vasc Interv Radiol 24:1657–63e1.
   PubMed Web of Science ®Google Scholar
• Deng G, Zhao DL, Li GC, et al. (2011). Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol 34:824–32.
   PubMed Web of Science ®Google Scholar
• Elsohly AM, Netirojjanakul C, Aanei IL, et al. (2015). Synthetically modified viral capsids as versatile carriers for use in antibody-based cell targeting. Bioconjug Chem 26:1590–6.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhao X, Yun Q, et al. (2015). Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 8:10388–400.
   PubMed Web of Science ®Google Scholar
• Gentil K, Lentz CS, Rai R, et al. (2014). Eotaxin-1 is involved in parasite clearance during chronic filarial infection. Parasite Immunol 36:60–77.
   PubMed Web of Science ®Google Scholar
• Gholamrezanezhad A, Mirpour S, Geschwind JF, et al. (2016). Evaluation of 70–150-mum doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. Eur Radiol 26:3474–82.
   PubMed Web of Science ®Google Scholar
• Gonzalez MV, Tang Y, Phillips GJ, et al. (2008). Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med 19:767–75.
   PubMed Web of Science ®Google Scholar
• Guan YS, He Q, Jin Y, Yao F. (2016). Development of CalliSpheres(R) embolic microspheres. Zhonghua Gan Zang Bing Za Zhi 24:549–51.
   PubMedGoogle Scholar
• Gupta S, Wright KC, Ensor J, et al. (2011). Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. Cardiovasc Intervent Radiol 34:1021–30.
   PubMed Web of Science ®Google Scholar
• Ha Y, Lee JB, Shim JH, et al. (2016). Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. Eur Radiol 26:3510–8.
   PubMed Web of Science ®Google Scholar
• Hong K, Khwaja A, Liapi E, et al. (2006). New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–7.
   PubMed Web of Science ®Google Scholar
• Hong K, Kobeiter H, Georgiades CS, et al. (2005). Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 16:1711–7.
   PubMed Web of Science ®Google Scholar
• Hronek JW, Reed M. (2015). Nursing implications of chemotherapy agents and their associated side effects in patients with pancreatic cancer. CJON Nurs 19:751–7.
   Web of Science ®Google Scholar
• Jain RK. (2012). Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 64:353–65.
   PubMed Web of Science ®Google Scholar
• Lankelma J, Dekker H, Luque FR, et al. (1999). Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703–7.
   PubMed Web of Science ®Google Scholar
• Laurent A, Wassef M, Chapot R, et al. (2004). Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol 15:491–6.
   PubMed Web of Science ®Google Scholar
• Lewis AL. (2009). DC bead: a major development in the toolbox for the interventional oncologist. Expert Rev Med Dev 6:389–400.
   PubMed Web of Science ®Google Scholar
• Lewis AL, Gonzalez MV, Lloyd AW, et al. (2006). DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–42.
   PubMed Web of Science ®Google Scholar
• Li XL, Guo WX, Hong XD, et al. (2016). Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Hepatol Res 46:1088–98.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–9.
   PubMed Web of Science ®Google Scholar
• Meng M, Gao J, Wu C, et al. (2016). Doxorubicin nanobubble for combining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor. Tumor Biol 37:8673–80.
   PubMed Web of Science ®Google Scholar
• Namur J, Citron SJ, Sellers MT, et al. (2011). Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 55:1332–8.
   PubMed Web of Science ®Google Scholar
• Namur J, Wassef M, Millot JM, et al. (2010). Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 21:259–67.
   PubMed Web of Science ®Google Scholar
• Namur J, Wassef M, Pelage JP, et al. (2009). Infrared microspectroscopy analysis of ibuprofen release from drug eluting beads in uterine tissue. J Control Release 135:198–202.
   PubMed Web of Science ®Google Scholar
• Oliveri RS, Wetterslev J, Gluud C. (2012). Hepatocellular carcinoma. Lancet 380:470. author reply 470–1.
   PubMed Web of Science ®Google Scholar
• Primeau AJ, Rendon A, Hedley D, et al. (2005). The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782–8.
   PubMed Web of Science ®Google Scholar
• Tao JJ, Visvanathan K, Wolff AC. (2015). Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast 24:S149–S53.
   PubMed Web of Science ®Google Scholar
• Tawada A, Chiba T, Ooka Y, et al. (2015). Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. Anticancer Res 35:549–54.
   PubMed Web of Science ®Google Scholar
• Tzeng WS, Wu RH, Chang SC, et al. (2008). Ionic versus nonionic contrast media solvents used with an epirubicin-based agent for transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 19:342–50.
   PubMed Web of Science ®Google Scholar
• Weinberg BD, Patel RB, Exner AA, et al. (2007). Modeling doxorubicin transport to improve intratumoral drug delivery to RF ablated tumors. J Control Release 124:11–9.
   PubMed Web of Science ®Google Scholar
• Yuan S, Zhang X, Lu L, et al. (2004). Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs 15:641–6.
   PubMed Web of Science ®Google Scholar
• Zheng JH, Chen CT, Au JL, Wientjes MG. (2001). Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 3:E15.
   PubMed Web of Science ®Google Scholar
• Zou JH, Zhang L, Ren ZG, Ye SL. (2016). Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 17:510–7.
   PubMed Web of Science ®Google Scholar